Clinical Trials Results Reporting Improved with Email Reminders
BMJ last month posted a research article that shows researchers are more likely to post the results of their trials if they are sent an email reminder.
BMJ last month posted a research article that shows researchers are more likely to post the results of their trials if they are sent an email reminder. Since 2007, the FDA has required registration of clinical trials conducted in the United States on ClinicalTrials.gov before they begin and to post summary results within one year of completion of the trial. However, about 75% of trials on ClinicalTrials.gov haven’t reported results. The BMJ study focused on Phase IV trials that were closed for recruitment with at least one site in the United States. The experimental intervention "consisted of sending reminders of the FDAAA 801 requirement through personalized emails to responsible parties of the randomly selected trials. The emails were constructed as surveys, notifying responsible parties of trials that the primary completion date was over a year old and asking for the reasons why they had not posted results on the register (see supplementary appendix). In fact the survey was a “cover” for the reminder." At three months, 19% trials in the intervention group had posted results versus 13% in the control group. At six months, 24% trials in the intervention group had posted results versus 14% in the control group.
Read the full report here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
